At the end of 2023, the FDA approved Casgevy for sickle cell disease, its first approval for a therapeutic that used the genome editing tool clustered regulatory interspaced palindromic repeats ...
Southwest Research Institute (SwRI) has developed a unique technology to screen new DNA-targeting therapeutics designed to treat cancer and other diseases. Combining SwRI's 3D drug screening software ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results